Development of DNA-biochips for rational prescription of psychopharmaceuticals (Q11681)

From EU Knowledge Graph
Revision as of 09:18, 28 November 2021 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in fr: translated_label)
Jump to navigation Jump to search
Project Q11681 in Czech Republic
Language Label Description Also known as
English
Development of DNA-biochips for rational prescription of psychopharmaceuticals
Project Q11681 in Czech Republic

    Statements

    0 references
    0 references
    0 references
    7,740,698.75 Czech koruna
    0 references
    309,627.95 Euro
    10 January 2020
    0 references
    11,073,961.0 Czech koruna
    0 references
    442,958.44 Euro
    10 January 2020
    0 references
    69.9 percent
    0 references
    31 October 2020
    0 references
    ESSENCE LINE, s.r.o.
    0 references
    0 references

    50°4'11.50"N, 14°22'51.56"E
    0 references

    50°4'6.46"N, 14°23'8.41"E
    0 references
    15000
    0 references
    15000
    0 references
    Cílem projektu je vyvinout nový DNA-biochip pro racionalizovanou preskripci psychofarmak pro pacienty s psychiatrickým onemocněním a tím přinést prospěch nejen pacientovi, ale snížit náklady zdravotních pojišťoven. Přínosem projektu bude bezpečnější a efektivnější preskripce psychofarmak, což povede k úspěšnější farmakoterapii, zvýší komfort pacienta v podobě pozitivní terapie a sníží náklady na neefektivně aplikovaná psychofarmaka a negativní dopady na pacienta. a. (Czech)
    0 references
    The aim of the project is to develop a new DNA-biochip for rationalised prescription of psychopharmaceuticals for patients with psychiatric diseases and thus bring benefits not only to the patient, but to reduce the costs of health insurance companies. The benefit of the project will be safer and more effective prescription of psychopharmaceuticals, which will lead to more successful pharmacotherapy, increase patient comfort in the form of positive therapy and reduce the cost of inefficiently applied psychopharmaceuticals and negative effects on the patient. a. (English)
    22 October 2020
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/17_107/0012433
    0 references